Verzenio
Payments companies reported to CMS as associated with Verzenio. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Verzenio, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Verzenio
These are the largest totals companies reported as associated with Verzenio. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Johnny Chang | Encino, CA | Hematology & Oncology | $181,580.19 |
| Sarmen Sarkissian | Mission Hills, CA | Hematology & Oncology | $149,907.22 |
| Peter Kaufman | Lebanon, NH | Medical Oncology | $139,496.28 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $138,209.92 |
| Kristi Orbaugh | Indianapolis, IN | Nurse Practitioner | $138,105.46 |
| Wassim Mchayleh | Altamonte Springs, FL | Hematology & Oncology | $107,337.39 |
| Andrew Seidman | New York, NY | Medical Oncology | $98,075.28 |
| Anne Odea | Westwood, KS | Medical Oncology | $94,391.14 |
| Fadi Braiteh | Las Vegas, NV | Medical Oncology | $93,283.04 |
| Mohammadbagher Ziari | Corona, CA | Hematology & Oncology | $90,567.30 |
Prescribed Verzenio?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.